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Purpose of the study
Combined antiretroviral therapy is associated with
atherosclerosis and cardiovascular complications. Since
patients receive various drugs simultaneously, it has been
difficult to determine the role of each particular antiretro-
viral group or specific agent in these side-effects. Although
clinical studies suggested protease inhibitors (PIs) as the
agents responsible for these complications, this issue
remains unclear. The present study was designed to ana-
lyze the acute effects of PIs on one of the first steps in the
pathogenesis of atherosclerosis, i.e. leukocyte recruit-
ment.
Methods
Leukocyte rolling, adhesion and emigration were moni-
tored in the mesenteric post-capillary venules of anaesthe-
tized rats by using intravital video microscopy. We
compared the effects of the protease inhibitor atazanavir,
lopinavir and indinavir (the two last boosted with ritona-
vir) administered orally 5 hr before the measurements.
Doses were chosen according to the literature in order to
generate plasma levels in animals similar to those clini-
cally present in humans. Data were compared using a one-
way analysis of variance followed by a Newman-Keuls
post hoc test. All experiments were performed in groups of
n ≥ 5 animals.
Summary of results
Acute administration of the proteases inhibitors lopinavir
(53, 106 mg/kg), boosted with ritonavir (13, 26 mg/kg,
respectively) or indinavir (20, 40 mg/kg), boosted with
ritonavir (20, 40 mg/kg, respectively) did not cause any
effect on leukocyte parameters. Acute administration of
the protease inhibitor atazanavir (100 mg/kg) promoted
a significant increase in leukocyte rolling flux (59.8 ± 16.6
vs. 32.5 ± 2.7 cells/min), adhesion (16.1 ± 4.3 vs. 3.77 ±
0.7 cells/100 μm, p < 0.001) and emigration (7.5 ± 1.7 vs.
3.63 ± 0.8 cells/field, p < 0.05) compared with animals
treated with vehicule. All values are mean ± SEM.
Conclusion
These studies indicate that acute exposure to atazanavir
induces leukocyte recruitment and suggest that atazanavir
could be responsible of precipitating the cardiovascular
diseases observed in HIV-infected patients treated with
protease inhibitors as part of combined antiretroviral
therapy.
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